摘要
目的探讨吉西他滨联合长春瑞滨治疗难治性非霍奇金淋巴瘤的临床疗效和用药安全性。方法通过对本院2007年1月至2011年6月21例难治性非霍奇金淋巴瘤患者采用吉西他滨1000mg/m2静脉滴注,第1和第8天,加入生理盐水静推50mL,第1天和第8天,静推后给予地塞米松加生理盐水快速滴注,化疗前后给予止吐药,21～28d为一个周期,2个周期后对患者病情进行一次评估。结果 21例患者其中CR2例(9.52%),PR8例(38.1%),SD 9例(42.86%),PD 2例(9.52%),总有效率47.62%;缓解期为(4.3±4.1)个月,1年生存率52.38%(11/21)。该药物组合的主要毒副作用是骨髓抑制和胃肠道反应。结论吉西他滨联合长春瑞滨对难治性非霍奇金淋巴瘤疗效好,副作用小,临床上值得推广。
Objective To investigate the gemcitabine plus vinorelbine in the treatment of refractory non-Hodgkin＇s lymphoma,the clinical efficacy and drug safety.Methods The hospital in January 2007,June 21,2011 patients with refractory non-Hodgkin＇s lymphoma were treated with intravenous infusion of gemcitabine 1000mg/m^2 the 1st and 8th day,normal saline bolus of 50ml,the first Days 1 and 8 days after giving dexamethasone bolus Songane rapid infusion of normal saline,before and after chemotherapy given antiemetic drugs,21-28d for a period of two cycles on an assessment of the patient＇s condition.Results 21 patients of which CR2 patients（9.52%）,PR8 patients（38.1%）,SD 9 例（42.86%）,PD 2 cases（9.52%）,the total efficiency 47.62%;remission of（4.3 ± 4.1） month,1-year survival rate 52.38%（11/21）.The main side effects of drug combination is bone marrow suppression and gastrointestinal reactions.Conclusion Gemcitabine plus vinorelbine in refractory non-Hodgkin＇s lymphoma,side effects,clinical worth promoting.
出处
《中国医药指南》
2012年第10期13-14,共2页
Guide of China Medicine
